Wave starts Phase Ib/IIa testing of HD candidates

Wave Life Sciences Ltd. (NASDAQ:WVE) began the Phase Ib/IIa PRECISION-HD1 and PRECISION-HD2 trials of WVE-120101 and WVE-120102, respectively, to treat patients with early manifest Huntington's disease (HD). PRECISION-HD1 will enroll patients who carry a single nucleotide polymorphism (SNP) at the rs362307 location, while PRECISION-HD2 will enroll patients with an SNP at the rs362331 location.

Both double-blind, placebo-controlled, international trials will evaluate single and multiple intrathecal doses of the allele-specific antisense therapies in about 50 patients across 4 dose-escalation cohorts. Wave told BioCentury the starting dose for the first cohort will be 2 mg, but declined to disclose how the dose will escalate for the multi-dose portion or for subsequent cohorts...